Showing results (201-210 of 245) with videos related to
Sort By:
Pageof 25
Clinical and Molecular Hepatology|March 11, 2025
Molecular Classification of Hepatocellular Carcinoma based on Zoned Metabolic Feature and Oncogenic Signaling PathwayTomoko Aoki, Naoshi Nishida, Yutaka Kurebayashi, et al.Oncology|December 19, 2016
Malignant Transformation of Hepatocellular AdenomaWing Yee Kwok, Satoru Hagiwara, Naoshi Nishida, et al.Liver Cancer|May 7, 2026
Clinical Prediction of Glycolysis-Driven Molecular Subclass of Hepatocellular Carcinoma without Transcriptomic ProfilingTomoko Aoki, Masatoshi Kudo, Satoshi Ogiso, et al.Liver Cancer|October 30, 2023
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept StudyMasatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, et al.Oncology|December 20, 2017
Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter StudyChikara Ogawa, Masahiro Morita, Akina Omura, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 21, 2026
Prospective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd-EOB-DTPA-MRITomoko Aoki, Masatoshi Kudo, Kazuomi Ueshima, et al.Journal for Immunotherapy of Cancer|June 16, 2022
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched studyBrett Marinelli, Edward Kim, Antonio D'Alessio, et al.Therapeutic Advances in Medical Oncology|May 17, 2021
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinomaTomi Jun, Umut Ozbek, Sirish Dharmapuri, et al.Journal of Gastroenterology|March 7, 2025
Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept studyTomoko Aoki, Masatoshi Kudo, Naoshi Nishida, et al.Frontiers in Oncology|March 3, 2023
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitorsY Linda Wu, Grace van Hyfte, Umut Özbek, et al.Pageof 25